Wells Fargo Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Wells Fargo analyst Derek Archila maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $145.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Archila is a 5-star analyst with an average return of 19.9% and a 54.18% success rate. Archila covers the Healthcare sector, focusing on stocks such as Incyte, Ascendis Pharma, and Soleno Therapeutics.
In addition to Wells Fargo, Rhythm Pharmaceuticals also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued on January 15. However, on January 16, TipRanks – OpenAI reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).
Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $51.3 million and a GAAP net loss of $52.9 million. In comparison, last year the company earned a revenue of $33.25 million and had a GAAP net loss of $43.64 million
Read More on RYTM:
Disclaimer & DisclosureReport an Issue
- Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
- Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
- Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue
